HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
DLGAP5
DLG associated protein 5
Chromosome 14 · 14q22.3
NCBI Gene: 9787Ensembl: ENSG00000126787.14HGNC: HGNC:16864UniProt: Q15398
95PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Hub Gene
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
spindle pole centrosomeprotein bindingmitotic spindlenucleusneurodegenerative diseaseplacenta praeviaplacental retentionmale infertility
✦AI Summary

DLGAP5 (DLG associated protein 5) is a mitotic spindle-associated protein with critical roles in cell cycle regulation and disease pathogenesis. Primary Function: DLGAP5 regulates spindle assembly and chromosome 14 through interaction with TACC3 1, and functions as a cell cycle regulator that promotes progression through G1/S phases 2. Mechanism: DLGAP5 operates through multiple protein-stabilization pathways: it stabilizes E2F1 transcription factor via USP11-mediated deubiquitination 3, stabilizes MYC protein through USP11 interaction creating positive feedback loops 4, and upregulates PLK1 to promote cell proliferation 5. In prostate cancer, TFAP4 transcriptionally activates DLGAP5, which subsequently activates JAK2/STAT3 signaling 6. Disease Relevance: Biallelic DLGAP5 variants cause spindle assembly defects leading to recurrent early embryonic arrest and female infertility 1. DLGAP5 overexpression drives malignancy across multiple cancers including lung adenocarcinoma, bladder cancer, prostate cancer, and glioblastoma, promoting proliferation, migration, invasion, and chemoresistance 54378. Clinical Significance: High DLGAP5 expression correlates with poor prognosis, advanced tumor stage, and resistance to immunotherapy and chemotherapy 2. DLGAP5 represents a promising diagnostic biomarker and therapeutic target; inhibitors including AT9283 and AAPK-25 show promise in suppressing tumor growth 57.

Sources cited
1
DLGAP5 deficiency disrupts spindle assembly through TACC3 interaction and causes recurrent early embryonic arrest
PMID: 40796344
2
DLGAP5 promotes cell proliferation through cell cycle G1 arrest regulation and correlates with poor prognosis and immunotherapy resistance in lung adenocarcinoma
PMID: 36712920
3
DLGAP5 stabilizes E2F1 via USP11-mediated prevention of ubiquitination, creating a positive feedback loop in bladder cancer
PMID: 38182895
4
DLGAP5 stabilizes MYC protein via USP11-mediated deubiquitination to enhance gemcitabine resistance in bladder cancer
PMID: 39990228
5
DLGAP5 promotes lung adenocarcinoma growth by upregulating PLK1 and is targeted by the inhibitor AT9283
PMID: 38414025
6
DLGAP5 mediates neuroendocrine differentiation in prostate cancer through E2F1 and is inhibited by AAPK-25
PMID: 39923838
7
DLGAP5 is upregulated in glioblastoma and promotes growth and M2 polarization of tumor-associated macrophages
PMID: 40944860
8
TFAP4 transcriptionally activates DLGAP5, which drives prostate cancer progression and macrophage M2 polarization via JAK2/STAT3 signaling
PMID: 40962169
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.49Moderate
placenta praeviaOpen Targets
0.26Weak
placental retentionOpen Targets
0.20Weak
male infertilityOpen Targets
0.18Weak
alcohol drinkingOpen Targets
0.16Weak
breast cancerOpen Targets
0.11Weak
neoplasmOpen Targets
0.11Weak
lung adenocarcinomaOpen Targets
0.11Weak
hepatocellular carcinomaOpen Targets
0.11Weak
Female infertility due to fertilization defectOpen Targets
0.09Suggestive
gliomaOpen Targets
0.08Suggestive
non-small cell lung carcinomaOpen Targets
0.08Suggestive
bladder transitional cell carcinomaOpen Targets
0.08Suggestive
HypercholesterolemiaOpen Targets
0.08Suggestive
triple-negative breast cancerOpen Targets
0.08Suggestive
cancerOpen Targets
0.08Suggestive
endometrial cancerOpen Targets
0.07Suggestive
posterior cortical atrophyOpen Targets
0.07Suggestive
central nervous system cancerOpen Targets
0.07Suggestive
oocyte maturation defect 14Open Targets
0.07Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
TPX2Protein interaction100%CDC20Protein interaction100%UBE2CProtein interaction99%KIF2CProtein interaction98%BIRC5Protein interaction97%BUB1Protein interaction97%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
54%
Lung
2%
Liver
1%
Heart
0%
Ovary
0%
Gene Interaction Network
Click a node to explore
DLGAP5TPX2CDC20UBE2CKIF2CBIRC5BUB1
PROTEIN STRUCTURE
Preparing viewer…
PDB7ZX4 · 2.08 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.11LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.92 [0.76–1.11]
RankingsWhere DLGAP5 stands among ~20K protein-coding genes
  • #5,025of 20,598
    Most Researched95 · top quartile
  • #11,399of 17,882
    Most Constrained (LOEUF)1.11
Genes detectedDLGAP5
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target.
PMID: 38414025
J Transl Med · 2024
1.00
2
Biallelic variants in DLGAP5 cause spindle assembly defects and human early embryonic arrest.
PMID: 40796344
Hum Reprod · 2025
0.90
3
DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization.
PMID: 39990228
Theranostics · 2025
0.80
4
DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11.
PMID: 38182895
Oncogene · 2024
0.70
5
PMID: 40416599
MedComm (2020) · 2025
0.60